Drug intelligence / Profile preview

PMN311

Development stage: Preclinical
Lead developer: ProMIS Neurosciences
Modality: Vaccines & Immunotherapeutics

Overview

PMN311 is a vaccine candidate developed by ProMIS Neurosciences for Alzheimer's disease. It is an Amyloid-Beta (Aβ) vaccine, specifically designed to target the oligomer target epitope of Aβ. This approach aims to induce an effective antibody response against pathogenic Aβ, potentially for prevention or therapeutic use in Alzheimer's disease.

Other names: Amyloid-Beta VaccineAβ vaccine

Targets

Aβ oligomers (Amyloid-β oligomers)

Beyond the preview

Go deeper on PMN311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMN311.

Explore the full profile